Open Access<p>The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells</p>
Author(s) -
Zhenyu Wang,
Wenhao Shen,
Xugang Li,
Yunjiang Feng,
Kun Qian,
GaoRen Wang,
Yiying Gao,
Xiaohui Xu,
Shuyu Zhang,
Ling Yue,
Jianping Cao
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s242557
Subject(s) - rosiglitazone , pancreatic cancer , radiosensitivity , cancer research , viability assay , cancer cell , mtt assay , clonogenic assay , cancer , agonist , chemistry , biology , cell , medicine , radiation therapy , receptor , biochemistry
As radiation therapy is widely used for the management of pancreatic cancer, identifying novel targets to improve the radiosensitivity of cancer cells is beneficial. Rosiglitazone, a specific peroxisome proliferator-activated receptor γ (PPARγ) agonist, has an inhibitory effect on various types of cancer cells. The purpose of this paper is to investigate the effect of rosiglitazone on the radiosensitivity of pancreatic cancer cells and the potential mechanism.